The truth is out there: an overall perspective on androgen deprivation.
Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.
Hellerstedt
Beth A
BA
Division of Hematology/Oncology, University of Michigan Medical Center, 1150 West Medical Center Drive, Box 0640, 5301 MSRB III, Box 0640, Ann Arbor, MI 48109, USA. bhellers@umich.edu
Pienta
Kenneth J
KJ
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000502:physiology*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013997:Time Factors
D000726:Androgen Antagonists; D000728:Androgens; D007987:Gonadotropin-Releasing Hormone